Roche silences Herceptin comparison

Share this article:

Biosimilar Herceptin is coming to India, but marketers will not be able to say so. The Wall Street Journal reported Friday that drugmaker Roche won a case that prevents the biosimilar manufacturer from using the brand name Herceptin in its marketing.

The decision also bars Biocon-Mylan from making comparisons between its lookalike breast cancer treatment's manufacturing processes, safety, efficacy and sales, with those of Herceptin.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.